Discovery and Development of Antiangiogenetic Drugs in Ovarian Cancer

New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies

“…Small molecule inhibitors targeting the kinase domain (KD) leading to blocking signaling pathway hence, suppression of tumor growth. 10 In 2007, sorafenib I turned into the first VEGFR-2 inhibitor 11 to be utilized in the treatment of hepatocellular carcinoma and renal cell carcinoma. 12 During the previous few decades, several VEGFR-2 inhibitors were designed as an adjunctive for cancer therapy.…”